Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Metastatic castrate-resistant prostate cancer (mCRPC) presents a significant clinical challenge with poor prognosis.
• Alterations in DNA damage response (DDR) genes are frequent in mCRPC, presenting therapeutic opportunities.
• Poly (ADP ribose) polymerase inhibitors (PARPi) leverage synthetic lethality in DDR-mutated cancers.

Purpose of the Study:

• To review the clinical efficacy and safety of combining PARPi with androgen receptor signaling inhibitors (ARSIs) in mCRPC.
• To analyze data from Phase III randomized controlled trials (RCTs) evaluating this combination therapy.
• To discuss patient selection strategies and emerging trends for PARPi plus ARSI treatment in mCRPC.

Main Methods:

• Systematic review of Phase III randomized controlled trials (RCTs) involving PARPi and ARSI combinations in mCRPC.
• Analysis of clinical efficacy and safety data, including antitumor activity and patient outcomes.
• Evaluation of treatment response in relation to DDR gene alterations and BRCAness phenotype.

Main Results:

• Phase III RCTs demonstrate improved antitumor activity with PARPi plus ARSI combination therapy versus ARSI monotherapy in first-line mCRPC.
• Clinical benefits are more pronounced in patients with DDR alterations, particularly BRCA1/2 mutations.
• Antitumor activity is also observed in patients without specific DDR mutations, suggesting a broader efficacy linked to the BRCAness phenotype and androgen receptor blockade.

Conclusions:

• The combination of PARPi and ARSI represents a promising therapeutic strategy for mCRPC, particularly in the first-line setting.
• Patient selection based on DDR alterations can optimize treatment outcomes, but efficacy extends beyond these specific mutations.
• Further research into patient selection and emerging trends will refine the use of PARPi plus ARSI in mCRPC management.